MX2014006756A - Celulas pulmonares fetales mamiferas y uso terapeutico de las mismas. - Google Patents

Celulas pulmonares fetales mamiferas y uso terapeutico de las mismas.

Info

Publication number
MX2014006756A
MX2014006756A MX2014006756A MX2014006756A MX2014006756A MX 2014006756 A MX2014006756 A MX 2014006756A MX 2014006756 A MX2014006756 A MX 2014006756A MX 2014006756 A MX2014006756 A MX 2014006756A MX 2014006756 A MX2014006756 A MX 2014006756A
Authority
MX
Mexico
Prior art keywords
same
therapeutic use
fetal pulmonary
mammalian fetal
pulmonary cells
Prior art date
Application number
MX2014006756A
Other languages
English (en)
Inventor
Yair Reisner
Elias Shezen
Chava Rosen
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of MX2014006756A publication Critical patent/MX2014006756A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0688—Cells from the lungs or the respiratory tract

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Se describe una composición farmacéutica que comprende como un ingrediente activo una población aislada de suspensión de células a partir de un tejido pulmonar fetal mamífero. El tejido pulmonar fetal está en una etapa de desarrollo correspondiente a aquella de un órgano/tejido pulmonar humano en una etapa gestacional seleccionada de un intervalo de aproximadamente 20 a aproximadamente 22 semanas de gestación. También se describen métodos para usar la composición farmacéutica.
MX2014006756A 2011-12-08 2012-12-06 Celulas pulmonares fetales mamiferas y uso terapeutico de las mismas. MX2014006756A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161568240P 2011-12-08 2011-12-08
PCT/IB2012/057042 WO2013084190A1 (en) 2011-12-08 2012-12-06 Mammalian fetal pulmonary cells and therapeutic use of same

Publications (1)

Publication Number Publication Date
MX2014006756A true MX2014006756A (es) 2015-03-09

Family

ID=47557423

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006756A MX2014006756A (es) 2011-12-08 2012-12-06 Celulas pulmonares fetales mamiferas y uso terapeutico de las mismas.

Country Status (19)

Country Link
US (1) US9833482B2 (es)
EP (2) EP2788009B1 (es)
JP (1) JP2015500279A (es)
KR (1) KR20140102730A (es)
CN (1) CN104105493A (es)
AU (1) AU2012348574A1 (es)
CA (1) CA2857930A1 (es)
ES (2) ES2673471T3 (es)
HK (1) HK1202809A1 (es)
HU (1) HUE030541T2 (es)
IL (1) IL233022A (es)
MX (1) MX2014006756A (es)
PH (1) PH12014501309A1 (es)
PL (1) PL2788009T3 (es)
PT (1) PT2788009T (es)
RU (1) RU2014127338A (es)
SG (1) SG11201402902VA (es)
WO (1) WO2013084190A1 (es)
ZA (1) ZA201404958B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201400513PA (en) 2011-09-08 2014-06-27 Yeda Res & Dev Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
HUE030541T2 (en) 2011-12-08 2017-05-29 Yeda Res & Dev Mammalian fetal lung cells and their therapeutic use
CN104977414B (zh) * 2014-04-09 2016-09-28 上海交通大学医学院 鉴定骨髓中是否存在保护白血病干细胞微环境的试剂盒及其应用
WO2016203477A1 (en) 2015-06-18 2016-12-22 Yeda Research And Development Co. Ltd. Conditioning protocols and use of same for tissue regeneration
JP7057748B2 (ja) * 2015-07-16 2022-04-20 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド 遺伝子改変された抗第三者中枢性メモリーｔ細胞および免疫療法におけるその使用
CN109475581A (zh) * 2016-05-22 2019-03-15 耶达研究及发展有限公司 为了移植及诱导耐受性而使用肺细胞的方法
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
US11555178B2 (en) 2017-01-18 2023-01-17 Yeda Research And Development Co. Ltd. Genetically modified veto cells and use of same in immunotherapy
US20210369786A1 (en) * 2017-10-27 2021-12-02 Alis Pharma Ltd. Fetal tissue extract, methods for producing the extract, and the use thereof
CN109529123B (zh) * 2018-11-08 2021-02-19 中国人民解放军第四军医大学 水凝胶、纳米纤维支架与皮肤细胞层层组装的血管化全层组织工程皮肤及其制备方法
EP3747992A1 (en) 2019-06-04 2020-12-09 Medizinische Hochschule Hannover Compositions and process for integrating cells into epithelium
CN111518761B (zh) * 2020-05-25 2022-04-29 青岛瑞思德生物科技有限公司 一种间充质干细胞体外筛选、激活、扩增、冻存及其细胞库建立的方法
WO2023105526A1 (en) 2021-12-08 2023-06-15 Yeda Research And Development Co. Ltd. Multipotent lung progenitor cells for lung regeneration

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5192553A (en) 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US5004681B1 (en) 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5656498A (en) 1994-02-22 1997-08-12 Nippon Telegraph And Telephone Corporation Freeze-dried blood cells, stem cells and platelets, and manufacturing method for the same
US6204053B1 (en) 1994-11-08 2001-03-20 Diacrin, Inc. Porcine cortical cells and their use in treatment of neurological deficits due to neurodegenerative diseases
US6110459A (en) 1997-05-28 2000-08-29 Mickle; Donald A. G. Transplants for myocardial scars and methods and cellular preparations
US5955257A (en) 1997-10-21 1999-09-21 Regents Of The University Of Minnesota Infusible grade short-term cell storage medium for mononuclear cells
US8609412B2 (en) * 1999-08-05 2013-12-17 Regents Of The University Of Minnesota Mapc generation of lung tissue
EP1099754A1 (en) 1999-11-10 2001-05-16 Universiteit Leiden Mesenchymal stem cells and/or progenitor cells, their isolation and use
US20040136972A1 (en) 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
US20030096016A1 (en) 2001-09-07 2003-05-22 Yeda Research And Development Co. Ltd. Methods of kidney transplantation utilizing developing nephric tissue
US20030215942A1 (en) 2002-02-14 2003-11-20 Stemcyte, Inc. Undesignated allogeneic stem cell bank
IL164048A0 (en) 2002-03-15 2005-12-18 Univ North Carolina Primitive and proximal hepatic stemcells
GB0304799D0 (en) 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
AU2005290849B2 (en) 2004-10-04 2009-09-03 Yeda Research And Development Co. Ltd. Disease treatment via developing non-syngeneic graft transplantation
US8628964B2 (en) * 2006-10-11 2014-01-14 Drexel University Fetal pulmonary cells and uses thereof
US20100034791A1 (en) * 2007-02-14 2010-02-11 Drexel University Engineered Lung Tissue Construction for High Throughput Toxicity Screening and Drug Discovery
WO2012047951A2 (en) * 2010-10-05 2012-04-12 The Brigham And Women's Hospital, Inc. Human lung stem cells and uses thereof
HUE030541T2 (en) 2011-12-08 2017-05-29 Yeda Res & Dev Mammalian fetal lung cells and their therapeutic use
KR102109643B1 (ko) 2011-12-22 2020-05-29 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 안정하고 장기적인 생착을 위한 병용 치료법
WO2016203477A1 (en) 2015-06-18 2016-12-22 Yeda Research And Development Co. Ltd. Conditioning protocols and use of same for tissue regeneration

Also Published As

Publication number Publication date
ZA201404958B (en) 2015-05-27
PT2788009T (pt) 2016-08-31
PL2788009T3 (pl) 2016-11-30
IL233022A0 (en) 2014-07-31
CN104105493A (zh) 2014-10-15
PH12014501309A1 (en) 2014-09-15
EP3034087A1 (en) 2016-06-22
IL233022A (en) 2017-12-31
HUE030541T2 (en) 2017-05-29
RU2014127338A (ru) 2016-02-10
HK1202809A1 (en) 2015-10-09
US9833482B2 (en) 2017-12-05
CA2857930A1 (en) 2013-06-13
NZ627071A (en) 2015-11-27
JP2015500279A (ja) 2015-01-05
EP3034087B1 (en) 2018-03-14
ES2587876T3 (es) 2016-10-27
KR20140102730A (ko) 2014-08-22
WO2013084190A1 (en) 2013-06-13
EP2788009A1 (en) 2014-10-15
US20140356335A1 (en) 2014-12-04
AU2012348574A1 (en) 2014-07-24
EP2788009B1 (en) 2016-05-25
ES2673471T3 (es) 2018-06-22
SG11201402902VA (en) 2014-07-30

Similar Documents

Publication Publication Date Title
PH12014501309A1 (en) Mammalian fetal pulmonary cells and therapeutic use of same
IL264430A (en) Methods for preparing human RPE cells and pharmaceutical preparations of human RPE cells
IL287381A (en) Pharmaceutical preparations of human rpe cells and their use
EA201270780A1 (ru) С-3 модифицированные производные бетулиновой кислоты в качестве ингибиторов созревания вич
MX2013002382A (es) Composiciones cutaneas y metodos para su uso.
IN2012DN06720A (es)
UA111770C2 (uk) Інгібітори бромдомену
IL204860A (en) Use of placenta containing mid-cd56 + natural killer cells for drug production
TN2011000174A1 (en) Compounds that expand hematopoietic stem cells
UA112425C2 (uk) ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ
NO20090598L (no) 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud
EP3257943A3 (en) Methods and vectors for cell immortalisation
WO2010082787A3 (ko) 연골줄기세포를 유효성분으로 포함하는 골질환 치료용 또는 항염증용 약제학적 조성물
SG193246A1 (en) Nutritional compositions for increasing arginine levels and methods of using same
MX2009011316A (es) Derivados del acido lipoico.
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
WO2008056368A3 (en) Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
EP2608797A4 (en) CD271 PRECURSOR CELLS FROM BONE MARROW FOR CARDIAC REPAIR
WO2013126590A3 (en) Pharmaceutical composition comprising cd34+ cells
EA201290694A1 (ru) Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназы
WO2013184193A3 (en) Cancer stem cells and methods of using the same
PA8802801A1 (es) Métodos para cocultivar células derivadas de sangre de cordón umbilical con células madres menstrualles
IL311307A (en) Alternative generation of human allogeneic T cells
WO2011043629A3 (ko) 인간 지방 줄기세포의 고활성을 유도하는 방법 및 배지
MX342859B (es) Polisacarido de las semillas de tamarindo para usarse en el tratamiento de enfermedades inflamatorias.